← Back to Screener
MAIA Biotechnology, Inc. (MAIA)
Price$1.33
Favorite Metrics
Price vs S&P 500 (26W)-25.53%
Price vs S&P 500 (4W)-10.52%
Market Capitalization$86.15M
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)2.13x
Cash Flow / Share (Quarterly)$-0.49
Price vs S&P 500 (YTD)-9.83%
EPS (TTM)$-0.71
10-Day Avg Trading Volume0.70M
EPS Excl Extra (TTM)$-0.71
EPS (Annual)$-0.70
ROI (Annual)-942.66%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-230.78%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-1208.97%
Cash Flow / Share (Annual)$-0.49
P/B Ratio36.26x
P/B Ratio (Quarterly)23.85x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-3091.02x
ROA (TTM)-201.78%
EPS Incl Extra (Annual)$-0.70
Current Ratio (Annual)1.66x
Quick Ratio (Quarterly)1.48x
3-Month Avg Trading Volume1.00M
52-Week Price Return-10.13%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.20
52-Week High$3.19
EPS Excl Extra (Annual)$-0.70
26-Week Price Return-21.55%
Quick Ratio (Annual)1.48x
13-Week Price Return-9.55%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.66x
Enterprise Value$77.496
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.22
3-Month Return Std Dev118.47%
Net Income / Employee (TTM)$-2
ROE (Last FY)-942.66%
Net Interest Coverage (Annual)-1441.91x
EPS Basic Excl Extra (Annual)$-0.70
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.71
ROI (TTM)-797.25%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.78
Price vs S&P 500 (52W)-39.96%
Year-to-Date Return-7.19%
5-Day Price Return18.33%
EPS Normalized (Annual)$-0.70
ROA (5Y Avg)-192.53%
Month-to-Date Return1.43%
EBITD / Share (Annual)$-0.71
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-1208.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.71
P/TBV (Quarterly)6.60x
P/B Ratio (Annual)23.85x
Book Value / Share (Annual)$0.06
Price vs S&P 500 (13W)-10.24%
Beta0.31x
Revenue / Share (TTM)$0.00
ROE (TTM)-797.25%
52-Week Low$0.87
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MAIAMAIA Biotechnology, Inc. | — | — | — | — | $1.33 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing THIO, an investigational drug candidate with dual anti-cancer mechanisms targeting telomeres and immune function. The lead program combines THIO with Regeneron's approved checkpoint inhibitor Libtayo (cemiplimab) to treat patients with advanced non-small cell lung cancer. The combination approach aims to enhance the immune system's ability to attack cancer cells.